Market Access
Value-Based Healthcare—Demonstrating Value in an Era of Increased Scrutiny and Accountability
Value-based care, value-based contracting, outcomes-based contracting, risk-based contracting—the emergence of these strategies have left ...
Small Drug Features May Have Big Value in the COVID World
When I was an access decision maker at a leading pharmacy benefit manager (PBM), ...
Three Changes for Patient Access Programs Following COVID-19’s Increase in Uninsured Patients
The long-term impacts of the COVID-19 pandemic—across the globe and in the U.S.—cannot be ...
Pharma Must Demonstrate Better Outcomes for Pay-Per-Performance
In the dramatically changing pharma industry, one key trend that overlays providers of care, ...
COVID-19: How are Payers Managing These Days?
If there’s one thing we know about payers, it’s they hate surprises. That’s why ...
Is Significant Change on the Horizon for Payers, Pricing, and Pharma?
Thanks to the 2020 presidential election, pharma companies can expect plenty of talk from ...
Two Key Questions About Payer Strategies in 2020
PM360 asked experts within market access strategies whether pricing regulation will impact 2020 and ...
Demonstrating Value in the Real World
New therapies are hitting the market at an unprecedented pace, and the innovation behind ...
Conglomerate of Dermatologists are Offering Patients a Solution to High Drug Prices
High drug prices is one issue—perhaps the only one—on which legislators on both side ...
The Next Chapter for Digital Therapeutics
Imagine you are a primary care physician (PCP) in a mid-sized Midwestern city. Over ...
Big Uptick in Patient Savings Delivered via EHR
With more than 90% of covered workers now facing a tiered formulary for prescription ...
Who Will Cover Innovation Costs in the Exam Room?
Perhaps no field is more rapidly innovating than medicine. New discoveries are being made ...
The World’s Most Expensive Drug
Priced at a staggering $2.125 million per patient, Zolgensma is now the world’s most ...